pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Endocrinology & Metabolism · news · pharmadog
← back to Endocrinology & Metabolism
News · Endocrinology & Metabolism
224
stories
6h
Roche pours $750M into Oregon manufacturing plant as obesity push expands
biospace
10h
Ultragenyx, after setbacks, nabs first gene therapy approval
biopharma dive
13h
STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
stat
15h
STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
stat
15h
STAT+: One of the most consequential years for cancer treatment, ever
stat
17h
Reduce protein to increase longevity? Nutrition experts say that’s a bad idea
stat
1d
FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia
fda press
1d
STAT+: Regeneron drug for disease that causes dangerous bone growth earns FDA approval
stat
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
1d
Enveda’s exercise-simulating obesity tablet clears early clinical test
biospace
1d
STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
stat
1d
STAT+: In wake of boy’s death, gene editing experts dissect Huidagene’s decisions
stat
2d
STAT+: Real-world psilocybin data suggest need for close monitoring
stat
2d
BioMarin acquires experimental drug for rare bone disorder in $275M deal
biopharma dive
2d
STAT+: Prominent AI startup rolls out virtual cell model in race to speed up science
stat
2d
Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia
biospace
2d
STAT+: Amylyx endocrine drug succeeds in pivotal study
stat
2d
STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
stat
2d
BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca
fiercebiotech
3d
Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win
fiercebiotech
6d
Skye and Redx form new entity with $125M to advance fibrosis assets
fiercebiotech
6d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
7d
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
7d
STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk
stat
7d
Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
fiercebiotech
8d
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
biospace
8d
After slimming down workforce, Aardvark scraps phase 3 trials as wait for next steps drags on
fiercebiotech
9d
Stopping statins in people over 75 at low risk for heart disease didn’t increase deaths
stat
9d
Amgen lays groundwork for new R&D center in Hyderabad
fiercebiotech
9d
STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?
stat
← prev
page 1 of 8
next →
